60 Degrees Pharmaceuticals, Inc. (SXTP) AI Stock Analysis
SXTP AI stock analysis summary
AI Research60 Degrees Pharmaceuticals, Inc. (SXTP) is a specialty pharmaceutical firm developing treatments for infectious diseases. Over the trailing twelve months, the company generated $1.2M in revenue with an operating margin of -1092.4%. SXTP carries a market capitalization of $3.0M and held $1.0M in cash and short-term investments as of June 30, 2026.
- Market cap
- $3.0M
- Revenue (TTM)
- $1.2M
- P/E
- —
- 1Y return
- -85.8% S&P 500 16.8%
- Avg. target
- $3.70 332.7% vs last close
Bull case
- The consensus mean price target of $3.70 implies an upside of 332.7% compared to the October 16, 2026 share price of $0.85.
- Analyst projections for the next fiscal year forecast revenue reaching $1.7M, representing 70.0% growth.
- The company maintains net cash of $871,427 with minimal total debt of $151,179 as of June 30, 2026.
Bear case
- Operating cash flow reached -$6.8M and free cash flow was -$7.1M in FY2025, while cash and short-term investments stood at $1.0M as of June 30, 2026.
- The company has demonstrated heavy dilution, with a five-year share count change of 10866.1%.
- SXTP stock fell 85.8% over the past year and closed at $0.85, near its 52-week low of $0.83.
What 60 Degrees Pharmaceuticals does
60 Degrees Pharmaceuticals, Inc. is a specialized pharmaceutical firm based in Washington, D.C., dedicated to advancing therapies for the prevention and treatment of infectious diseases across the United States. Established in 2010, the company develops and commercializes treatments including Arakoda for malaria prevention. Its pipeline includes Tafenoquine in Phase IIb trials for COVID-19 and Phase IIA trials for babesiosis, fungal pneumonias, and candidiasis. The company is also researching Celgosivir to target respiratory viruses and dengue.
Growth and profitability
Revenue increased to $1.0M in FY2025, up 65.5% from $607,574 in FY2024, following 139.6% growth in FY2024 from $253,573 in FY2023. However, the five-year revenue CAGR from FY2020 to FY2025 stands at -14.3%. Operating losses remained large, with operating margins recording -1599.0% in FY2024 and -771.6% in FY2025. Net income was -$7.9M in FY2024 and -$7.4M in FY2025. For the latest quarter ending June 30, 2026, quarterly revenue growth declined 32.5% year-over-year, and trailing twelve months EPS was -$5.34.
Balance sheet and cash flow
As of June 30, 2026, the company held $1.0M in cash and short-term investments alongside total debt of $151,179, resulting in net cash of $871,427. Its current ratio was 2.32, and the debt-to-equity ratio stood at 0.06 with shareholders' equity of $2.6M. Cash flow remains negative, with free cash flow of -$7.1M and operating cash flow of -$6.8M in FY2025. In FY2025, capital expenditures totaled $218,084, and the five-year share count increased 10866.1%.
Valuation and performance
SXTP trades at an enterprise value of $12.7M and a market capitalization of $3.0M. Its price-to-sales multiple is 2.5x, below the 4.1x median of its US-listed Healthcare peers. The company trades at an EV/EBITDA of 22.2x, compared to the peer median of 12.0x, and an EV-to-revenue ratio of 11.5x. Over the past year, SXTP shares declined 85.8%, underperforming the S&P 500 (SPY) return of 16.8%.
What analysts expect
Wall Street coverage consists of 1 Strong Buy and 1 Hold rating. The mean price target is $3.70, representing a 332.7% premium over the last close of $0.85 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate revenue of $1.0M and EPS of -$3.45. For the next fiscal year, one analyst estimates revenue of $1.7M and EPS of -$3.58. Over the last 4 quarters, the company recorded 0 EPS beats. The next earnings date is November 12, 2026.
Key risks and what to watch
- Ongoing cash burn is significant relative to liquidity, with free cash flow of -$7.1M in FY2025 against $1.0M in cash and short-term investments as of June 30, 2026.
- Quarterly revenue dropped 32.5% year-over-year in the period ending June 30, 2026.
- The company recorded 0 EPS beats over the trailing four quarters, showing inconsistency against consensus earnings estimates.
- Stock volatility is elevated, reflected by a beta of 2.40 and a 57.9% year-to-date decline.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this SXTP AI stock analysis
This page is an AI-written research summary of 60 Degrees Pharmaceuticals, Inc. (SXTP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: SXTP income statement, SXTP balance sheet, SXTP key metrics, SXTP analyst forecast, SXTP chart. See the SXTP stock overview for the latest quote and news.
SXTP AI stock analysis FAQ
What products and pipeline candidates does SXTP have?
The company offers Arakoda for malaria prevention. Its pipeline includes Tafenoquine in clinical trials for COVID-19, babesiosis, fungal pneumonias, and candidiasis, as well as Celgosivir targeting respiratory viruses and dengue.
What is SXTP's current financial position?
As of June 30, 2026, SXTP had $1.0M in cash and short-term investments, $151,179 in total debt, and a current ratio of 2.32. Trailing twelve months revenue stood at $1.2M.
What are analysts projecting for SXTP?
For the fiscal year ending December 31, 2026, analysts estimate revenue of $1.0M and EPS of -$3.45. For the next fiscal year, one analyst forecasts revenue to increase 70.0% to $1.7M with EPS of -$3.58.
Does SXTP pay a dividend?
SXTP does not pay a dividend. The company generated -$7.1M in free cash flow during FY2025 as it funds operations and drug development.